{"created":"2023-06-19T10:43:41.753967+00:00","id":3972,"links":{},"metadata":{"_buckets":{"deposit":"3b8458f9-d0af-4029-ac0b-d3603264e90d"},"_deposit":{"created_by":11,"id":"3972","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"3972"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00003972","sets":["30:293:294","30:57:269","77:78:79"]},"author_link":["2890","8611","2792","2909","675","6456","6322","674","8612"],"item_4_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-09","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"5","bibliographicPageEnd":"2974","bibliographicPageStart":"2969","bibliographicVolumeNumber":"35","bibliographic_titles":[{},{"bibliographic_title":"In vivo (Athens, Greece)","bibliographic_titleLang":"en"}]}]},"item_4_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"小出, 博義"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"野田, 哲史"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"吉田, 哲也"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"影山, 進"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"寺村, 和也"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"加藤, 威"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"河内, 明宏"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"藤本, 徳毅"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"寺田, 智祐"}],"nameIdentifiers":[{},{}]}]},"item_4_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background:\nWe report two cases in which severe skin disorders developed during sorafenib treatment in patients with renal cell carcinoma (RCC) who had previously received nivolumab. ","subitem_description_type":"Abstract"},{"subitem_description":"Case report:\nCase 1: A 50-year-old man with RCC received nivolumab as the fifth-line therapy followed by sorafenib as the sixth-line therapy. On day 15 of sorafenib administration, the patient was hospitalized with systemic erythema multiforme, acne-like skin rash, and hand-foot syndrome. Case 2: A 40-year-old man with RCC received nivolumab as the second-line therapy followed by sorafenib as the fifth-line treatment. On day 12 of sorafenib administration, the patient was hospitalized with an acne-like skin rash and hand-foot syndrome. The skin disorders in the two cases improved within 2-3 weeks after sorafenib discontinuation and the start of treatment with topical and oral steroids. ","subitem_description_type":"Abstract"},{"subitem_description":"Conclusion:\nWhen using sorafenib in patients previously treated with nivolumab, close attention should be paid to the onset of serious skin disorders. ","subitem_description_type":"Abstract"}]},"item_4_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Journal Article","subitem_description_type":"Other"}]},"item_4_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"International Institute of Anticancer Research"}]},"item_4_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"34410996","subitem_relation_type_select":"PMID"}}]},"item_4_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.21873/invivo.12591"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.21873/invivo.12591","subitem_relation_type_select":"DOI"}}]},"item_4_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. "}]},"item_4_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1791-7549","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"KOIDE, Hiroyoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"NODA, Satoshi"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"YOSHIDA, Tetsuya"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"KAGEYAMA, Susumu"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"TERAMURA, Kazuya"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"KATO, Takeshi"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"KAWAUCHI, Akihiro"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"FUJIMOTO, Noriki"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"TERADA, Tomohiro"}],"nameIdentifiers":[{},{}]}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Sorafenib","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"immunotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"nivolumab","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"renal cell carcinoma","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"skin disorder","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients."}]},"item_type_id":"4","owner":"11","path":["79","269","294"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-09-15"},"publish_date":"2021-09-15","publish_status":"0","recid":"3972","relation_version_is_last":true,"title":["Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients."],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-06-19T11:22:12.010997+00:00"}